rood blauwe elepsis logo Belegger.nl

BioPharma Terug naar discussie overzicht

GNBT !!!

2.656 Posts
Pagina: «« 1 ... 35 36 37 38 39 ... 133 »» | Laatste | Omlaag ↓
  1. positivo73 4 januari 2006 22:19
    nabeurs van 0,83 naar 0,87. Gaat er wat gebeuren? Opletten mensen, als er toestemming voor fase 3 aankomt dan kunnen we m.i. zo naar de $2.
    m.v.g.Willem
  2. [verwijderd] 4 januari 2006 22:59
    nabeurs:

    01/04/06 16:32:38 0.880 0.880 0.880 100
    01/04/06 16:28:08 0.880 0.880 0.880 1,800
    01/04/06 16:25:08 0.870 0.870 0.870 100
    01/04/06 16:23:38 0.860 0.860 0.860 1,800
    01/04/06 16:22:08 0.860 0.860 0.860 1,900
    01/04/06 16:14:38 0.880 0.870 0.880 2,900
    01/04/06 16:13:08 0.880 0.880 0.880 100
    01/04/06 16:11:38 0.890 0.890 0.890 4,200
    01/04/06 16:10:08 0.900 0.848 0.848 25,900
    01/04/06 16:08:38 0.850 0.840 0.840 1,200
    01/04/06 16:05:39 0.830 0.830 0.830 200
    01/04/06 15:59:39 0.840 0.840 0.840 300

    host.businessweek.com/businessweek/Hi...
  3. positivo73 5 januari 2006 15:21
    quote:

    rac69 schreef:

    Pre-Market (RT-ECN): 0.91 0.07 (8.33%)
    Jaaaaaaaaaaaaaaa, zo wil ik het zien. Bedankt voor het posten Rac, kan zelf weer niks volgen.
    m.v.g.Willem
  4. [verwijderd] 5 januari 2006 15:24
    quote:

    GTCBeliever schreef:

    [quote=rac69]
    Pre-Market (RT-ECN): 0.91 0.07 (8.33%)
    [/quote]
    Jaaaaaaaaaaaaaaa, zo wil ik het zien. Bedankt voor het posten Rac, kan zelf weer niks volgen.
    m.v.g.Willem
    ik zag het staan en dacht zal willem is ff blij maken op zijn werk.:-)
  5. positivo73 5 januari 2006 15:25
    quote:

    Striker_ schreef:

    op tradingday en yahoo.com kan je alles prima volgen??
    Thuis wel, maar op het werk zijn deze sites geblokkeer :-((((((.
    m.v.g.Willem
  6. [verwijderd] 5 januari 2006 15:27
    Press Release Source: Generex Biotechnology

    Generex Biotechnology Granted United States Patent in Connection With Its RapidMist(TM) Device
    Thursday January 5, 9:00 am ET

    New Patent Expands Protection for RapidMist

    TORONTO--(MARKET WIRE)--Jan 5, 2006 -- Generex Biotechnology Corporation (NasdaqSC:GNBT - News), a leader in the area of buccal drug delivery, announced today that it has been granted another United States patent. The patent entitled, "Cleaning Compounds for and Method of Cleaning Valves and Actuators of Metered Dose Dispensers Containing Pharmaceutical Compositions," relates to the formulation and methodology for cleaning the Company's proprietary RapidMist device which is designed to deliver pharmaceutical products, including Oral-lyn(TM), the Company's proprietary oral insulin product, into the buccal cavity (the mouth) where it is absorbed into the bloodstream.
    ADVERTISEMENT


    The patent covers a method of cleaning the RapidMist metered dose spray device, and a cleaning composition for such cleaning, to prevent the device from becoming clogged with medication. The cleaning composition is non-toxic and will not harm the user of the device following cleaning. This process makes the RapidMist device suitable for long-term, chronic use and ensures the accuracy and efficacy of the metered medication doses.

    About Generex

    Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Oral-lyn(TM)), which has been approved for commercial sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. Antigen Express is a wholly owned subsidiary of Generex. The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases.

    For more information, visit the Generex Web site at www.generex.com.

    Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

    Contact:
    Contacts:
    Shayne Gilliatt
    Generex Biotechnology Corporation
    1-800-391-6755
    +1-416-364-2551

    Ed Lewis
    CEOcast, Inc.
    +1-212-732-4300


    --------------------------------------------------------------------------------
    Source: Generex Biotechnology
  7. positivo73 5 januari 2006 15:35
    Mijn Engels is niet zo goed, maar ik krijg het idee dat het pb wel ok is. Reageert de koers nog een beetje?
    m.v.g.Willem
  8. positivo73 5 januari 2006 18:28
    Met 15 minuten vertraging 0,89 met een omzet van 1.330.000. Stijgen met zo'n omzet geeft mij voor de korte termijn erg veel vertrouwen.
    m.v.g.Willem
  9. positivo73 5 januari 2006 18:52
    Heeft iemand een volledig overzicht van wat er in de laat op 0,89 en 0,90 staat. Er zijn er volgens mij al een hele hoop gegaan op 0,89.
    m.v.g.Willem
  10. [verwijderd] 6 januari 2006 09:26
    Ik snap er helemaal niets van dat we al niet boven een Dollar staan.
    Ik wweet zeker dat het goed komt,toesemming komt steeds dichter bij.
    Kan niet lang meer duren voor we onze zakkken goed vol hebben.

    Nog een tip voor die gene die nog niet gekocht hebben,nu doen anders kan je wel eens een stuk duurder uit zijn.

    Groet, Ronald.
  11. positivo73 6 januari 2006 10:22
    Ik snap het denk ik wel. Ze houden de koers steeds laag om lekker veel naar binnen te harken, maar tot nu toe mag de koers niet onder de 0,80 komen. Ik denk dat we binnen een paar weken een mega bericht gaan krijgen en dan hebben de boefjes lekker veel stukjes voor weinig.
    m.v.g.Willem
2.656 Posts
Pagina: «« 1 ... 35 36 37 38 39 ... 133 »» | Laatste |Omhoog ↑

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.124
AB InBev 2 5.538
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 52.217
ABO-Group 1 25
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.875
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 192
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.848
Aedifica 3 926
Aegon 3.258 323.086
AFC Ajax 538 7.092
Affimed NV 2 6.305
ageas 5.844 109.906
Agfa-Gevaert 14 2.063
Ahold 3.538 74.353
Air France - KLM 1.025 35.295
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.051
Alfen 16 25.305
Allfunds Group 4 1.517
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 425
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.959
AMG 971 134.450
AMS 3 73
Amsterdam Commodities 305 6.745
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 496
Antonov 22.632 153.605
Aperam 92 15.063
Apollo Alternative Assets 1 17
Apple 5 386
Arcadis 252 8.807
Arcelor Mittal 2.034 320.999
Archos 1 1
Arcona Property Fund 1 287
arGEN-X 17 10.355
Aroundtown SA 1 221
Arrowhead Research 5 9.751
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.623
ASML 1.766 110.324
ASR Nederland 21 4.513
ATAI Life Sciences 1 7
Atenor Group 1 522
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.958
Axsome Therapeutics 1 177
Azelis Group 1 67
Azerion 7 3.449